Joonghun Pharmaceutical acquires European CE mark for 6 of its Hyaluronic Acid Dermal Fillers, Lorient



SEOUL, South Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) — A total of 6 products from the Lorient product line of cross-linked hyaluronic acid dermal fillers developed by Joonghun Pharmaceutical (CEO Sukjoon Yoon) have received the CE mark.

Lorient is a premium cross-linked hyaluronic dermal filler that has established a foothold for entry into the European beauty market by proving the safety and quality suitable for global standards through the acquisition of this European certification.

Lorient is intended to be injected into the subcutaneous layer of the skin to temporarily improve facial wrinkles in adults. Hyaluronic acid is a bio-friendly component that is present in the human skin, skeleton and synovial fluid and has qualities of lubrication and moisturizing.

Sukjoon Yoon, CEO of Joonghun Pharmaceutical has said “We wanted to make dermal fillers like the medicines that we make, through strict production management beyond the minimum requirements for

Read More